Document is current

Any future updates will be listed below

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

Crossref DOI link: https://doi.org/10.1007/s10637-015-0258-y

Published Online: 2015-06-19

Published Print: 2015-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark